| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1941511c81d94e81c7fd44228a50df40 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 |
| filingDate |
2018-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef25fdc0d12e68f15fdccbffb1addbd1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_058c5be490681d9c937732e74acbde50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_203fdbeffacf1b938d5738a9122eae28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d0870adcdf47c59a0f738e2f081477b |
| publicationDate |
2019-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019040399-A1 |
| titleOfInvention |
GLP-2 FUSION POLYPEPTIDES AND USES THEREOF FOR TREATING AND PREVENTING GASTROINTESTINAL DISORDERS |
| abstract |
The invention relates to GLP-2-F region immunoglobulin fusion proteins. GLP-2 and Fc regions are separated by a linker composed of amino acids. Fusion proteins remain and remain active in the body for longer periods than GLP-2 alone. Methods of using the fusion proteins of the invention to treat and prevent enterocutaneous fistulas, radiation damage to the gastrointestinal tract, obstructive jaundice and short bowel syndrome are further described. . |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11512065-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11279702-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021198195-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021263040-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11407768-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3870214-A4 |
| priorityDate |
2017-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |